Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2021-08-26

FDA Approved: LATISSE — Supplemental Application (Allergan, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for LATISSE (bimatoprost) by Allergan, Inc. The document records the approval status of the supplemental submission.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LATISSE (BIMATOPROST)

Snippet

SUPPL AP for LATISSE (BIMATOPROST)